{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:26:20Z","timestamp":1781843180246,"version":"3.54.5"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006677","name":"Washington State Department of Health","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013382","name":"Institute of Translational Health Sciences","doi-asserted-by":"publisher","award":["UL1TR002319"],"award-info":[{"award-number":["UL1TR002319"]}],"id":[{"id":"10.13039\/100013382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Collaborative care models that utilize pharmacists can expand hepatitis C (HCV) treatment access, but little is known about primary care provider (PCP) views on such models of care. We characterized PCP experiences of HCV treatment and assessed acceptability of leveraging pharmacists to treat HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We surveyed a convenience sample of Washington (WA) State PCPs regarding HCV treatment, experience of collaborating with pharmacists, and comfort with pharmacists managing HCV care. We report summarized descriptive statistics of survey responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventy-three PCPs completed the survey, 55% of whom prescribe buprenorphine for opioid use disorder. Nineteen percent directly treat HCV. Forty-five percent were aware of collaborative practice agreements (CPAs) and 22% reported interest in establishing a CPA to treat HCV. Most respondents were comfortable or extremely comfortable with pharmacists managing key elements of HCV care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In a sample of WA State PCPs, of whom greater than half prescribe buprenorphine for OUD, fewer than 1 in 5 directly treat HCV. Comfort with pharmacists managing most components of HCV treatment was high, but a minority of PCPs were familiar with or interested in establishing CPAs. Additional efforts are needed to leverage pharmacists to treat HCV, including among people who use drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21501319251359547","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:56Z","timestamp":1753891976000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of Pharmacists and Collaborative Practice Agreements to Treat Hepatitis C: A Survey of Primary Care Clinicians in Washington State"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1980-6579","authenticated-orcid":false,"given":"Jocelyn R.","family":"James","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine, Seattle, USA"},{"name":"Harborview Adult Medicine Clinic, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emalie","family":"Huriaux","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Tumwater, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Stockton","sequence":"additional","affiliation":[{"name":"Washington State Department of Health, Tumwater, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-464X","authenticated-orcid":false,"given":"Allison","family":"Cole","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-5399","authenticated-orcid":false,"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30297"},{"key":"e_1_3_3_3_2","unstructured":"CDC. Viral Hepatitis Surveillance- United States 2018-2022. Accessed October 30 2024. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2022surveillance\/hepatitis-c\/table-3.7.htm"},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 2016. World Health Organization Advocacy Brief. Accessed October 30 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016.04_eng.pdf?sequence=1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.2291"},{"key":"e_1_3_3_6_2","volume-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","author":"American Association for the Study of Liver Diseases and Infectious Disease Society of America","year":"2024","unstructured":"American Association for the Study of Liver Diseases and Infectious Disease Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases and Infectious Disease Society of America; 2024."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108525"},{"key":"e_1_3_3_8_2","unstructured":"Hep C Free Washington Washington State Department of Health Office of Infectious Disease. Plan to Eliminate Hepatitis C in Washington State by 2030. 2019. Accessed October 30 2024. https:\/\/doh.wa.gov\/sites\/default\/files\/legacy\/Documents\/Pubs\/150nonDOH-HepCFreeWA-PlanJuly2019.pdf"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009370"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0118"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108438"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001573"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2022.220427R1"},{"key":"e_1_3_3_14_2","unstructured":"WHO. Updated recommendations on HCV simplified service delivery and HCV diagnostics: policy brief. 2022. Accessed October 30 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240052697"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108684"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103924"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221125428"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2021.0142"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190018777345"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14014"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/2150132718807520"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-024-02507-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1715163513492642"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.02.014"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz365"},{"key":"e_1_3_3_26_2","unstructured":"Center for Health Law and Policy Innovation. Hepatitis C: State of Medicaid Access. Center for Health Law and Policy Innovation. 2024. Accessed October 30 2024. https:\/\/stateofhepc.org\/report-cards\/"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251359547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501319251359547","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319251359547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:23:24Z","timestamp":1777508604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501319251359547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":25,"alternative-id":["10.1177\/21501319251359547"],"URL":"https:\/\/doi.org\/10.1177\/21501319251359547","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"21501319251359547"}}